ASX Announcement

UPDATE ON STATUS OF FIRB APPROVAL

7 November 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (**Mayne Pharma**) refers to its proposed acquisition by Cosette Pharmaceuticals, Inc. (**Cosette**) by way of scheme of arrangement (**Scheme**).

On the evening of 6 November 2025, Mayne Pharma was notified that the Foreign Investment Review Board (**FIRB**) had unilaterally extended the statutory deadline for FIRB approval to 14 November 2025.

As previously announced on 4 November 2025, the Court hearing to approve the Scheme (**Second Court Hearing**) has been rescheduled to take place at 8.30am (AEDT) on Tuesday, 18 November 2025.

The Scheme remains subject to FIRB approval, Court approval and other conditions as set out in the Scheme Booklet (and as outlined in clause 3.1 of the Scheme Implementation Deed). On the basis that these conditions are satisfied, an updated indicative timetable is set out below. This timetable remains subject to ASX approval.

Event	Expected Date
Second Court Hearing to Approve the Scheme	Tuesday, 18 November 2025 at 8:30am AEDT
Effective Date Mayne Pharma shares will be suspended from trading at the close of trading on ASX on the Effective Date. If the Scheme proceeds, this will be the last day that Mayne Pharma shares will trade on ASX	Wednesday, 19 November 2025
Scheme Record Date For determining entitlements to the Scheme consideration	Friday, 21 November 2025 at 7:00pm AEDT
Scheme Implementation Date All Scheme shareholders will be sent the Scheme consideration to which they are entitled on this date	Monday, 1 December 2025

This timetable is indicative only. All dates and times, unless otherwise indicated, refer to the date and time in Australian Eastern Daylight Savings Time. Any changes to the above timetable will be announced to ASX and notified on Mayne Pharma's website at maynepharma.com.

If FIRB approval is received prior to 14 November 2025, Mayne Pharma may ask the Court to bring forward the date for the Second Court Hearing. Mayne Pharma will keep shareholders updated if such a request is made.

Mayne Pharma Shareholders do not need to take any action at this time.

- ENDS -

Mayne Pharma Group Limited
ABN 76 115 832 963
maynepharma.com
1538 Main North Road, Salisbury South, SA 5106 Australia

Authorised for release to the ASX by the Board Chair

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.